Unravelling the pathophysiology of HUS in light of recent discoveries on complement activation
|
|
- Arline Blake
- 5 years ago
- Views:
Transcription
1 Unravelling the pathophysiology of HUS in light of recent discoveries on complement activation Marina Noris November 13,
2 THROMBOTIC MICROANGIOPATHY Histology lesions: Swelling and detachment of endothelial cells, accumulation of fluffy material in the subendothelium, thrombi and obstruction of the vessel lumina. Ischemia Stenosis Endothelial injury subendothelial espansion Stenosis Organ dysfunction Thrombosis Thrombocytopenia 2 Shear stress RBC fragmentation Ruggenenti and Remuzzi, Kidney Int, 2001
3 dhus Stx Adhesion molecules and P-selectin up-regulation ahus Gene mutation Defective complement regulation TTP ADAMTS13 UL-VWF multimers stma Autoimmune or systemic diseases, glomerulopathies, tx, infections Complement activating conditions Microthrombi 3
4 ATYPICAL HEMOLYTIC UREMIC SYNDROME Ryan ahus Incidence: 0.5-2/1,000,000/year Sex: no difference 4 Patients free of events Death or ESRD (%) CFH mutation Follow up (years) 10 12
5 Prevalence of low C3 P < Prevalence of low C4 60 (%) 40 P = (% %) 10 0 Cases Controls Cases Controls 0 Cases Controls Cases Controls Relatives Relatives Within families, subjects with lower than normal C3 serum levels had a relative risk of HUS of 16.5 as compared to subjects with normal C3 levels 5 Noris et al., J Am Soc Nephrol, 1999
6 COMPLEMENT ACTIVATION PATHWAYS Classical pathway IgM, IgG Immune complexes Lectin pathway Mannose residues Alternative pathway bacteria, bacterial toxin, LPS, tick-over C1q,C1r,C1s MBL, MASP C3 C3a C1-est inhib C4,C2 Factor B Factor H C4bp C4bC2a Bb C3 convertase C3 convertase C3 C3a CR1 Factor I DAF MCP C3 C3a C4bC2a () 2 Bb C5 convertase C5 C5 convertase 6 C5a C5b-9 (MAC) CD59
7 Factor H plays a pivotal role in the regulation of the alternative pathway of complement activation Produced mainly in the liver as a single peptide glycoprotein, factor H circulates in plasma at a concentration of 50 mg/dl Regulatory domain Recognition doman proteoglycans proteoglycans Y118Ifs*4 L98F R53C S58A R60G C66Y c.155delagaa Y235C C309W Q400K c.1494dela C597stop C630W C673Y S714stop c.2303insa E850K M823T C853Y - >100 different genetic abnormalities in about 30% of patients - 90% are heterozygous, most in the recognition domain Q950H Y951H T956M I970V W978C S890I H893R Y899D Y899stop C915S Q924stop C926F c.22686del15bp Y1021F C1043R W1037stop Q1076E D1119G D1119N P1130L V1134G E1135 Q1137L Y1142D Y1142C W1157R C1163W c.3486dela c g>a P1166L V1168stop I1169L E1172stop Y1197C W1183L, W1183R W1183C T1184R L1189R L1189F S1191L S1191W G1194D E1195stop V1197A E1198A, E1198K F1199S V1200L R1203W G1204E R1206C R1210C, S1211P R1215G,R1215Q T1216stop C1218R P1226S c.3675_3699del c.3695_3698del Warwicker et al., Kidney Int, 1998 Caprioli et al., JASN, 2001 Richards et al., Am J Hum Gen, 2001 Perez-Caballero et al., Am J Hum Gen, 2001 Dragon-Durey et al., J Am Soc Nephrol, 2004 Caprioli et al., Blood, 2006 Noris et al, CJASN 2010
8 Fluid phase C3 convertase domain Alternative pathway activation (spontaneous hydrolysis, bacteria, viruses) recognition C- FH -N regulatory CFB FD Bb CFI CFH via regulatory domain dissociates Bb from and favors inactivation i C3 CFH via recognition domain binds on endothelium and regulates complement on cell surface C3a CFB FD CFI i CFI Bb Glycosaminoglycans Endothelial cell 8
9 SINGLE AMINO ACID CHANGES IN SCR 20 OF FACTOR H AFFECT ENDOTHELIAL CELL BINDING co HUVEC incubated with recombinant wild type or mutated factor H stained with fluorescinated anti-factor H antibody and analyzed by FACS Factor H R1210C Factor H Flow cytometry 9 Factor H R1210C WT Factor H Manuelian et al, J Clin Invest, 2003
10 CONSEQUENCES OF CFH MUTATIONS C- 20 CFH Fluid phase C3 convertase Alternative pathway activation (spontaneous hydrolysis, bacteria, viruses) -N CFB C3 Bb CFI i C3a 20 CFB CFI i Surface bound C3 convertase Bb C5 C5a C5 convertase 10 Glycosaminoglycans Endothelial cell
11 HIGH HOMOLOGY IN THE REGULATORS OF COMPLEMENT ACTIVATION GENE CLUSTER CFH/CFHR1 hybrid gene High degree of sequence identity between the gene for factor H and the genes for the five factor H-related proteins (CFHR1 to 5) which favors non-allelic homologous recombinations giving rise to hybrid genes. Copy number variation assays are required to detect hybrid genes 11 Venables et al., Plos Medicine 2006 Valoti et al, JASN 2015
12 CFH/CFHR HYBRID PROTEINS FOUND IN PATIENTS WITH ahus CFH/CFHR Venables et al., PLoS Med 2006 CFH/CFHR Valoti et al., JASN, 2015 CFH/CFHR Francis et al., Blood, 2012 CFH/CFHR Challis et al., Blood, 2015 In the CFH/CFHR hybrid molecules the C-terminal SCRs of CFH are substituted with those of CFHR1 or with the entire CFHR3, resulting in decreased complement regulatory activity on endothelial cell surface
13 HOMOZYGOUS DELETION OF CFHR1-CFHR3 GENES IS ASSOCIATED WITH FORMATION OF ANTI-CFH AUTOANTIBODIES CFH CFHR Blanc et al., J Immunol, 2012 Eight percent of patients (mostly children) develop anti-cfh autoantibodies Most patients with ahus and CFH autoantibodies are homozygous for a deletion of genes encoding CFH related proteins 1 and 3 Jozsi et al, Blood, 2008 Moore et al, Blood 2010 Failure of central and/or peripheral tolerance to FH related 1 in subjects completely lacking CFHR1? 13
14 MCP VARIANTS IN ahus spontaneous hydrolysis, bacteria, viruses 1 C35X C35Y (n=3) E36X P50T R59X (n=4) C64P K65D C3 SCRs 2 192T>C del C99R R103W G130V (96-129)del+G130I+Y132T+L133X STP 3 4 Y189D G204R T267fs270X ( )del+D277N+P278S F242C C3a TM A353V Y328X CFB CT MCP 10% CFI MCP i Endothelial cell Loss of function heterozygous variants: low expression or reduced binding and cofactor activity 14 Noris et al, Lancet 2003 Richards et al, PNAS 2003 Caprioli et al, Blood 2006
15 C3 IN ahus β-chain α-chain MG1 MG2 MG3 MG4 MG5 MG6β LNK ANA α NT MG6α MG7 CUB g TED CUB f MG8 Anchor C345C T140R T140K Q163E C3 7-10% R456L R570W K1029M R1041S D1093N I1135T T1361M C3 C3a CFB CFB C3 convertase CFI C5 MCP i Bb C5 convertase Glycosaminoglycans Gain of function C3 mutations: reduced binding to MCP and CFH, increased affinity to CFB Endothelial cell Goicoechea et al., PNAS, 2007 Roumenina et al., Blood, 2009 Fremeaux-Bacchi et al, Blood 2008
16 GENETICS OF AHUS: AN EUROPEAN DISCOVERY CFH CFH/CFHR1 hybrid MCP Newcastle 1 Jena C3 2 3 anti FH Ab Paris ~60% Del CFHR3/CFHR13 THBD CFI Bergamo Madrid CFB
17 COMBINED COMPLEMENT GENE ABNORMALITIES IN ahus 795 patients from 4 European cohorts 8.7% 8.2% 10% 22.6% 27% Combined complement gene abnormalities were found in about one quarter of patients with MCP or CFI mutations, and in around 10% of patients with CFH or C3 or CFB mutations 17 Bresin et al, JASN 2013
18 THREE CFH COMMON POLYMORPHISMS TAGGING THE H3 HAPLOTYPE ARE STRONGLY ASSOCIATED WITH AHUS Genotypes Odds Ratios (95 % C.I.) P value -332C/T Promoter c.2016a/g (p.q672q, SCR11) c.2808g/t (p.e936d,scr16) -332T+c.2016G+p.936D High risk < < < Caprioli et al., Hum Mol Genet, Pickering et al., J Exp Med, 200
19 TRIGGERING /UNDERLYING CONDITIONS % of HUS patients URT infection Diarrhea Pregnancy Others (malignant hypertension, glomerulopathy, de novo post-tx, systemic diseases) 0 CFH MCP CFI C3 Gene mutations 19 Noris et al, CJASN 2010
20 Trigger C3 C3a Eculizumab A humanized monoclonal antibody that binds to C5 PMP CD40L CFI CFB C3 convertase C3 C5 convertase C5a Coagulation Platelet aggregation MCP Bb Bb C5 C5b C5b-9 VWF Endothelial cell Endothelial cell 20 Modified from Noris and Remuzzi, NEJM 2009
21 LONG TERM OUTCOME OF ahus PATIENTS 100 Patients fre ee of events Death or ESRD (%) MCP mutation THBD mutation C3 mutation No mutation CFI mutation CFH mutation Follow up (years) Noris et al CJASN 2010
22 Platelet count mean change from baseline Estimated GFR mean change from baseline (x10-9 /liter) (ml/min) Months of Eculizumab treatment Months of Eculizumab treatment 26 Treatment effect was sustained for up to 26 months Licht et al., Kidney Int, 2015
23 Both during the acute phase of the disease and at remission about half of ahus patients had normal serum C3 and plasma sc5b-9 levels 23
24 SOLID-PHASE RESTRICTED COMPLEMENT ACTIVATION IN ahus 20 CFH Alternative pathway activation (spontaneous hydrolysis, bacteria, viruses) CFB CFI C3 Bb i Solid-phase restricted ahus C3a 20 CFB CFI i Surface bound C3 convertase Bb C5 C5a C5 convertase 24 Glycosaminoglycans Endothelial cell
25 SERUM FROM ahus PATIENTS CAUSES C5b-9 FORMATION ON ACTIVATED HMEC-1 REGARDLESS ON MUTATION STATUS HMEC-1 ADP 10µM 10 min -Control or ahus serum (n=29, in remission no eculizumab) (n=7 in acute phase) Static incubation 4 hours - anti-c5b-9 Ab staining - Confocal microscopy C5b-9 deposition 10,000 CFH CFI C3 CFB anti CFH Ab no mut 8,000 C5b-9 formed (pixel 2 ) 6,000 4,000 2,000 Ctr 0 scr Excessive C5b-9 deposits were observed with serum from all ahus patients (with or without identified complement abnormalities) during acute or remission phase. Noris et al., Blood, 2014
26 euro per patient per year (in child) Every 15 days forever? 26
27 RISK OF ATYPICAL HEMOLYTIC UREMIC SYNDROME RELAPSE AFTER ECULIZUMAB DISCONTINUATION 38 patients (24 women - 9 children and 29 adults) % of ahus relapse-free patients MCP variant No variant detected CFH variant months Fakhouri et al, CJASN, 2017 Among 52 case reports discontinuing eculizumab 16 (31%) had a subsequent TMA. In eculizumab clinical trials 12/61 patients who discontinued eculizumab experienced 15 TMA complications. TMA relapse occurred irrespective of identified genetic mutations, high risk polymorphism or auto-antibodies. Macia et al, Clin Kidney J, 2017
28 How to monitor and possibly tapering? 28
29 Terminal complement inhibitors Preclinical Phase I Eculizumab: ALXN1210: anti-c5 Ab blocks C5 cleavage (Alexion) Anti-C5 antibody (Alexion) Coversin RA Tesidolumab Zimura Phase II Phase III Approved ABP959 Eculizumab ALXN1210 SKY59 CCX-168 REGN3918 ALN-CC5 ALN-CC5: sirna Targeting C5 (Alnylam) CCX-168: C5aR antagonist (Chemocentrix) Coversin: Small C5 inhibitor (Akari) RA101495: cyclic peptide, C5 inhibitor (RaPharma) Tesidolumab: Anti-C5 antibody (Novartis) Zimura: aptamer-based C5 inhibitor (Ophthotech) 11 complement-targeted drug candidates in preclinical 29 ABP959: REGN3918: SKY59: Anti-C5 antibody (Amgen) Anti-C5 antibody (Regeneron) Anti-C5 antibody (Roche)
30 Multiple choice questions 1) Which of the following statements is correct? Atypical hemolytic uremic syndrome is caused by: a) fluid phase complement activation b) activation of the complement classical pathway on cell surface c) activation of the alternative complement pathway on cell surface d) impaired complement activation 2) Which among the following genes is not altered in atypical hemolytic uremic syndrome? a) Complement factor H (CFH) b) ADAMTS13 c) Complement C3 (C3) d) Membrane cofactor protein (MCP)
31 Multiple choice questions 3) Which among the following approaches is correct to diagnose atypical hemolytic uremic syndrome? a) Exclude an ADAMTS13 deficit b) Exclude an ADAMTS13 deficit and shiga-toxin producing bacteria c) Wait for the results of genetic screening d) Measure serum C3 levels
32 Next webinar: Membranous Nephropathy Jack Wetzels (Nijmegen) November 27,
33 These slides belong to Marina Noris, Ph.D. Mario Negri Institute for Pharmacological Research, Bergamo, Italy. Using these slides is only authorized when mentioning the source 33
Recent advances in pathogenesis & treatment of ahus
Recent advances in pathogenesis & treatment of ahus Miquel Blasco Pelicano Nephrology and Kidney Transplant Unit Hospital Clínic, Barcelona Atypical Hemolytic Uremic Syndrome (ahus) Ultra-rare disease:
More informationAcquired Drivers of Disaese ahus and autoantibodies: their role in disease and their impact on patient management
Acquired Drivers of Disaese ahus and autoantibodies: their role in disease and their impact on patient management Veronique Fremeaux-Bacchi Cordeliers Research Center and Européen Georges Pompidou Hospital,
More informationNew insights in thrombotic microangiopathies : TTP and ahus
New insights in thrombotic microangiopathies : TTP and ahus Dr Catherine LAMBERT Hematology Cliniques universitaires Saint-Luc Catherine.lambert@uclouvain.be New insights in thrombotic microangiopathies
More informationR. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk
R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy Lindsay Keir Richard
More informationC3 Glomerulopathy. Jun-Ki Park
C3 Glomerulopathy Jun-Ki Park 03.08.11 For the last 30 years classification MPGN is based on glomerular findings by light microscopy with further specification on EM and staining for Ig and complement
More informationHemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
More informationA Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples
A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples Sona Pekova, MD., PhD. Chambon Ltd., Laboratory for molecular diagnostics, Prague, Czech
More informationAtypical hemolytic uremic syndrome. Diana Karpman Department of Pediatrics Lund University
Atypical hemolytic uremic syndrome Diana Karpman Department of Pediatrics Lund University Image courtesy of Dr. Sabine Leh, Haukeland University Hospital, Bergen Norway Hemolytic Uremic Syndrome Non-immune
More informationAtypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Mouhanna Abu Ghanimeh 1, Omar Abughanimeh 1, Ayman Qasrawi 1, Abdulraheem
More informationSpectrum of complement-mediated thrombotic microangiopathies after kidney transplantation
Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Marius Miglinas Vilnius university hospital: Nephrology center, Center of Rare Kidney Diseases Vilnius university
More informationahus: recent insights and management
ahus: recent insights and management Steven Van Laecke MD, PhD Renal Division, Ghent University Hospital, Belgium 13 th BANTAO Sarajevo October 8 2017 The complement is everywhere I could benefit from
More informationPhysiologie du complément et son implication dans la pathologie rénale
Physiologie du complément et son implication dans la pathologie rénale Veronique Frémeaux-Bacchi Hôpital Européen Georges Pompidou Paris veronique.fremeaux-bacchi@aphp.fr Conflicts of Interest Served as
More informationM.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.
M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic
More informationHemolytic uremic syndrome
Hemolytic uremic syndrome Doyeun Oh Department of Internal Medicine CHA University School of Medicine Disclosures for Doyeun Oh Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationRecurrence of C3G after renal transplantation. Moglie Le Quintrec Service de Néphrologie, Hôpital Foch CRC, UMRS 1138, Equipe complement and diseases
Recurrence of C3G after renal transplantation Moglie Le Quintrec Service de Néphrologie, Hôpital Foch CRC, UMRS 1138, Equipe complement and diseases New MPGN classification C3G MPGN I DDD C3GN IF C3 deposits
More informationTMA CASE STUDY. Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit
TMA CASE STUDY Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit Cumulative fraction of patients free of events ahus is a catastrophic disease that can result in sudden & progressive
More informationHUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI
HUS and TTP Testing Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI Disclosures Relevant Financial Relationships Consultant: Ablynx, Bayer, CSL Behring,
More informationThrombotic Microangiopathy (TMA) The Clinical Facets of TMA
International Consensus on Management Atypical Hemolytic Uremic Syndrome in Children Loirat C. et al. Pediatr Nephrol 31: 15-39, 2016 Ruth A. McDonald, MD Professor and Vice Chair Clinical Affairs Department
More informationTherapeutic Complement Intervention Michael Kirschfink, Institute of Immunology, University of Heidelberg, Germany
Therapeutic Complement Intervention Michael Kirschfink, Institute of Immunology, University of Heidelberg, Germany Complement-mediated diseases Therapeutic intervention The complement system is involved
More informationw ahus pathology is linked to dysregulation of the alternative complement pathway.
ahus - Pathogenesis, Etiology, and Clinical Advances Craig B. Langman MD The Isaac A Abt MD Professor of Kidney Diseases Feinberg School of Medicine, Northwestern University Head, Kidney Diseases The Ann
More informationahus: Facts, Controversies & Treatment Updates Patrick D. Brophy MD Pediatric Nephrology, Dialysis & Transplant University of Iowa
ahus: Facts, Controversies & Treatment Updates Patrick D. Brophy MD Pediatric Nephrology, Dialysis & Transplant University of Iowa DISCLOSURE STATEMENT I, Patrick Brophy disclose the following relationships.
More informationSacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam
Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research, Amsterdam Sacha Zeerleder, MD PhD Internist-hematologist Academic Medical Centre, Amsterdam Sanquin Research,
More informationRisk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy
Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris WWA SFH
More informationThrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics
Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular Genetics Helen Liapis, M.D. Senior Consultant Arkana Labs Professor of Pathology & Immunology. retired Washington University School
More informationCore Curriculum in Nephrology
Core Curriculum in Nephrology Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core
More informationChallenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School
Challenges in Renal Apheresis Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School Outline Principles of Separation ASFA Guidelines Renal
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SP281 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid, 3 Chantal
More informationIntroduction to pathogenesis and treatment of thrombotic microangiopathies (TMA)
Introduction to pathogenesis and treatment of thrombotic microangiopathies (TMA) JM.Campistol, Nephrology and Renal Transplant Department, Hospital Clinic, University of Barcelona, Barcelona, Spain. jmcampis@clinic.cat
More informationDynamics of complement activation in ahus and how to monitor eculizumab therapy
Regular Article CLINICAL TRIALS AND OBSERVATIONS Dynamics of complement activation in ahus and how to monitor eculizumab therapy Marina Noris, 1 Miriam Galbusera, 1 Sara Gastoldi, 1 Paolo Macor, 2 Federica
More informationComplement. History. Chapter 7. Complement Components. Complement Pathways. Pathways of complement activation
History Chapter 7 Complement Jules Border in 1890 s discovered complement Paul Ehrlich coined the term complement The activity of blood serum that completes the action of antibody Now: Set of serum proteins
More informationTHROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11
THROMBOTIC MICROANGIOPATHY Jun-Ki Park 7/19/11 TMAs are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes.
More informationHistory. Chapter 13. Complement Components. Complement Pathways
History Chapter 13 Complement Jules Border in 1890 s discovered complement Paul Ehrlich coined the term complement The activity of blood serum that completes the action of antibody Now: Set of serum proteins
More informationLes microangiopathies thrombotiques Quoi de neuf?
Les microangiopathies thrombotiques Quoi de neuf? Société des Sciences Vasculaires du Québec 16 Septembre 2016 Anne-Laure Lapeyraque CHU Sainte Justine, Montréal anne.laure.lapeyraque@umontreal.ca Objectifs
More informationIntroduction. A system of soluble enzymes and proteins. Complement components: C1 to C9, B, D and P
Complement Introduction A system of soluble enzymes and proteins Complement components: C1 to C9, B, D and P When activated, each component is split into small and large (major) fragments a b *A horizontal
More informationSpecialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus)
Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus) Document Author: Assistant Director for Evidence, Evaluation and Effectiveness Executive Lead: Medical Director
More informationHistory. Chapter 13. Complement Components. Complement Pathways
History Chapter 13 Complement Jules Border in 1890 s discovered complement Paul Ehrlich coined the term complement The activity of blood serum that completes the action of antibody Now: Set of serum proteins
More informationClinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome
Hindawi Publishing Corporation Advances in Hematology Volume 214, Article ID 295323, 7 pages http://dx.doi.org/1.1155/214/295323 Clinical Study Therapy Leads to Rapid Resolution of Thrombocytopenia in
More informationEculizumab as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Adult Living-Related Kidney Transplantation
Anti-C5 as Prophylactic Therapy in Atypical Hemolytic Uremic Syndrome in Living- Related Kidney Transplantation Authors: Miquel Blasco 1, Santiago Rodríguez de Córdoba 2, Fritz Diekmann 1, Mercedes Saiz
More informationFrom MPGN to C3G. F Fakhouri, Nantes, France. «Membranoproliferative» is a pathological feature. Mesangial expansion «Doubles contours»
From MPGN to C3G F Fakhouri, Nantes, France Conflits d intérêt: consultant auprès d Alexion Pharmaceuticals «Membranoproliferative» is a pathological feature Mesangial expansion «Doubles contours» Immune
More informationNovel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab
Nephrol Dial Transplant (2014) 29: iv131 iv141 doi: 10.1093/ndt/gfu235 Full Review Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab Jacobien C. Verhave 1, Jack F.M. Wetzels
More informationTMA in HUS and TTP: new insights
TMA in HUS and TTP: new insights Daan Dierickx University Hospitals Leuven, Department of Hematology, Belgium 20th Annual Meeting Belgian Society on Thrombosis and Haemostatis Antwerpen, 22 th November
More informationUntying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome
REVIEW Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Han-Mou Tsai, MD imah Hematology Associates, New Hyde Park, NY. ABSTRACT Patients presenting with microangiopathic
More informationNot So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura
Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura Robert A. Brodsky, MD Johns Hopkins Family Professor
More informationTwo Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations
American Journal of Transplantation 2013; 13: 2201 2206 Wiley Periodicals Inc. Case Report C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationTopic (6): The Complement System
Topic (6): The Complement System Introduction The complement system is a complex system of many different glycoproteins. It comprises several plasma proteins that sequentially activate each other by proteolytic
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SA-PO546 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid,
More informationAn update on the the lectin pathway of complement
An update on the the lectin pathway of complement Laboratory of Molecular Medicine Department of Clinical Immunology, Section 7631 Rigshospitalet Copenhagen Denmark E-mail: garred@post5.tele.dk Malmø,
More informationHemolytic Uremic Syndrome
Hemolytic Uremic Syndrome Francesco Emma Division of Nephrology and Dialysis Bambino Gesù Children s Hospital, IRCCS Rome, Italy Hemolytic Uremic Syndrome (HUS) microangiopathic hemolytic anemia thrombocytopenia
More informationComplement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna
Complement in vasculitis and glomerulonephritis Andy Rees Clinical Institute of Pathology Medical University of Vienna 41 st Heidelberg Nephrology Seminar March 2017 The complement system An evolutionary
More informationHaemolytic uraemic syndrome the story of a whodunit
Haemolytic uraemic syndrome the story of a whodunit Paul Warwicker Lancashire Teaching Hospitals NHS Trust RCP Kidney for the General Physician Conference Nov 17 Renal thrombotic microangiopathy (TMA)
More informationWhat is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
More informationAnastasios E. Germenis
Anastasios E. Germenis Professor and Chairman Department of Immunology & Histocompatibility School of Medicine University of Thessaly University Hospital of Larissa Greece agermen@med.uth.gr The Complement
More informationEculizumab in ahus: where do we stand in Prof. Fadi Fakhouri Dept. of nephrology and immunology, CHU de Nantes.
Eculizumab in ahus: where do we stand in 2016 Prof. Fadi Fakhouri Dept. of nephrology and immunology, CHU de Nantes. INSERM UMR S-1064 Thrombotic microangiopathy: evolving concepts ST-HUS Coagulation mediated-tma
More informationahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.
To learn more about ahus, visit www.ahussource.com ahus A PATIENT S GUIDE Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved. SOL 1169 BECOME EMPOWERED By learning more and taking control
More informationPathology note 8 BLEEDING DISORDER
Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more
More informationComplement and the atypical hemolytic uremic syndrome in children
Pediatr Nephrol (2008) 23:1957 1972 DOI 10.1007/s00467-008-0872-4 EDUCATIONAL REVIEW Complement and the atypical hemolytic uremic syndrome in children Chantal Loirat & Marina Noris & Véronique Fremeaux-Bacchi
More informationCan eculizumab be discontinued in ahus? Case report and review of the literature
Clinical Case Report Medicine Can eculizumab be discontinued in ahus? Case report and review of the literature Tuncay Sahutoglu, MD a,, Taner Basturk, MD a, Tamer Sakaci, MD a, Yener Koc, MD a, Elbis Ahbap,
More informationDRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)
Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus
More informationmodified dye uptake assay including formazan test EC 90 not tested plaque reduction assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
More informationWhen a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus?
When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus? ADAMTS13 activity >5% RULES OUT a diagnosis of severe ADAMTS13 deficiency (TTP)
More informationPathogenetic mechanisms in atypical HUS
Pathogenetic mechanisms in atypical HUS Seppo Meri University & University Hospital Helsinki, Finland Antalya, Turkey Photo: Markku Kallio 21.10.2017 HUS after eating Kebab - 22 yo female - watery diarrhea
More informationKidney disease associated with autoimmune disease
Kidney disease associated with autoimmune disease Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan M-type Phospholipase A2 Receptor as
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, et al. Eculizumab
More informationC3 Glomerulonephritis versus C3 Glomerulopathies?
Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 2016 C3 Glomerulonephritis versus C3 Glomerulopathies? T. Keefe Davis Washington University School of Medicine
More informationSoliris and You. Your Guide To Living With ahus. INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)
INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab) INDICATION What is SOLIRIS? SOLIRIS is a prescription medicine called a monoclonal antibody. SOLIRIS is used to treat: adults and children
More informationDr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL
Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL CASE HISTORY 4 yrs old previously well boy Born to 2 nd degree consanguinity Fever x 5 days
More informationComplement mediated renal disease. Tim Goodship Institute of Genetic Medicine Newcastle University
Complement mediated renal disease Tim Goodship Institute of Genetic Medicine Newcastle University Evidence of complement activation is IgA and HSP Membranous Lupus nephritis ANCA associated Anti-GBM MPGN,
More informationPathology of Complement Mediated Renal Disease
Pathology of Complement Mediated Renal Disease Mariam Priya Alexander, MD Associate Professor of Pathology GN Symposium Hong Kong Society of Nephrology July 8 th, 2017 2017 MFMER slide-1 The complement
More informationSUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation
SUPPLEMENTARY INFORMATION Rare independent mutations in renal salt handling genes contribute to blood pressure variation Weizhen Ji, Jia Nee Foo, Brian J. O Roak, Hongyu Zhao, Martin G. Larson, David B.
More informationAtypical hemolytic uremic syndrome (ahus)
Sunday, July 12 10:00-18:30 Registration open I. Atypical hemolytic uremic syndrome (ahus) Chairs: Kronenberg, Speth 13:00 L1 ahus Role of complemet, overview Meri, FI 13:30 L2 ahus Role of lectin pathway
More informationBasic Immunology. Lecture 16th. Complement system
Basic Immunology Lecture 16th Complement system Components: Inactive factors in the serum and body fluids which can activate each other in an enzyme cascade Cell surface receptors (CR) for binding the
More informationTHE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES
THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 19 th EHA Congress, Milan, Italy, on 12 th June 2014 Chairperson Pier Mannuccio
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/140173
More informationDiseases of complement dysregulation an overview
Seminars in Immunopathology (2018) 40:49 64 https://doi.org/10.1007/s00281-017-0663-8 REVIEW Diseases of complement dysregulation an overview Edwin K. S. Wong 1,2 & David Kavanagh 1,2 Received: 5 September
More informationThrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome
Sallée et al. BMC Nephrology 2013, 14:3 RESEARCH ARTICLE Open Access Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome Marion Sallée 1, Khalil Ismail 1, Fadi Fakhouri 2, Henri
More informationHUS-MPGN-TTP. & related disorders
ES-PCR 4 th International Conference HUS-MPGN-TTP & related disorders Current diagnosis and therapy of hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN), thrombotic thrombocytopenic
More informationThrombotic microangiopathy and indications for therapeutic plasma exchange
SPIN DOCTORS:APHERESIS FOR HEMATOLOGISTS Thrombotic microangiopathy and indications for therapeutic plasma exchange Jill Adamski 1 1 Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona,
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor of Medicine and Oncology Division Chief Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to:
More informationInitial management of TMA syndromes
Initial management of TMA syndromes Elie Azoulay, Saint-Louis Hospital, Medical Intensive Care Unit Paris Diderot Sorbonne University Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique
More informationSoliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
More informationSoliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus)
Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (ahus) New Data from the Largest Prospective Trial of Adult Patients
More informationA PATIENT S JOURNEY. Learning about atypical hemolytic uremic syndrome (ahus)
A PATIENT S JOURNEY Learning about atypical hemolytic uremic syndrome (ahus) Begin your path to empowerment Being diagnosed with ahus can be overwhelming. You may have many questions: What is ahus? How
More informationCurrent evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
Clinical Kidney Journal, 2016, 1 10 doi: 10.1093/ckj/sfw115 Original Article ORIGINAL ARTICLE Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
More informationFabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.
Fabry Disease X-linked genetic, multi-organ disorder Fabry disease screening program in Hypertrophic p Cardiomyopathy: y preliminary results. Globotriaosylceramide, GL3 Brain -galactosidase A Eyes Lactosylceramide
More informationMedical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug
Medical Policy Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug Related Policies None DISCLAIMER Our medical policies are designed for informational purposes only and are not
More informationTHE COMPLEMENT SYSTEM OBJECTIVES:
Dr Mohammed Al- ani THE COMPLEMENT SYSTEM OBJECTIVES: When you finish this section, you should be able to: 1. Describe the effects of complement activation. 2. Outline the Classical, Mannan-Binding (MB)
More informationTo test the possible source of the HBV infection outside the study family, we searched the Genbank
Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),
More informationReview Article Kidney Diseases Caused by Complement Dysregulation: Acquired, Inherited, and Still More to Come
Clinical and Developmental Immunology Volume 2012, Article ID 695131, 6 pages doi:10.1155/2012/695131 Review Article Kidney Diseases Caused by Complement Dysregulation: Acquired, Inherited, and Still More
More informationComplement pathways: Classical pathway Alternative pathway Lectin pathway
Complement Complement pathways: Classical pathway Alternative pathway Lectin pathway Complement proteins Classical pathway C1q C1r C1s C4 C2 Alternative pathway D C3 B Lectin pathway MBL MASP-1 MASP-2
More informationA CAREGIVER S JOURNEY
A CAREGIVER S JOURNEY Learning about atypical hemolytic uremic syndrome (ahus) Begin your path to effective advocacy and support Caring for someone who is diagnosed with ahus can be overwhelming. You may
More informationThrombotic thrombocytopenic purpura: a look at the future
Thrombotic thrombocytopenic purpura: a look at the future Andrea Artoni, MD Ph.D. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, Italy andrea.artoni@policlinico.mi.it
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: eculizumab_soliris 8/2014 4/2018 4/2019 4/2018 Description of Procedure or Service Paroxysmal nocturnal hemoglobinuria
More informationTarget cell lysis Opsonization Activation of the inflammatory response (e.g. degranulation, extravasation) Clearance of immune complexes
Immunology Dr. John J. Haddad Chapter 13 Complement Major roles of complement (Figure 13-1): Target cell lysis Opsonization Activation of the inflammatory response (e.g. degranulation, extravasation) Clearance
More informationThrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13
Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists
More informationC3 GLOMERULOPATHIES. Budapest Nephrology School Zoltan Laszik
C3 GLOMERULOPATHIES Budapest Nephrology School 8.30.2018. Zoltan Laszik 1 Learning Objectives Familiarize with the pathogenetic mechanisms of glomerular diseases Learn the pathologic landscape and clinical
More informationDiagnosis and Treatment of Common TMAs
Diagnosis and Treatment of Common TMAs K. Pavenski, MD FRCPC St. Michael s Hospital June 13, 2014 Disclosures I have a relevant conflict of interest - Alexion Pharmaceuticals Inc. Participated in advisory
More informationSoliris Medical Policy Prior Authorization Program Summary
Soliris Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent of the Soliris
More informationNot So Benign Hematology. Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology
Not So Benign Hematology Robert A. Brodsky, MD Johns Hopkins Family Professor Director of Adult Hematology Disclosures Dr. Brodsky serves as a Scientific Advisory Board member to: Alexion Pharmaceuticals
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More information